GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry a deep trial record: STEP studied semaglutide for weight management (NEJM 2021), SURMOUNT studied tirzepatide for weight management (NEJM 2022), and SURMOUNT-OSA studied tirzepatide for obstructive sleep apnea (NEJM 2024)
WeGovy, on the other hand, goes between just under 30% more and around 20% less than the periodic average
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Ismaiel A.A., Papenbrock J
The potential for severe reactions, such as hormonal imbalances or increased blood pressure, further underscores the need for caution
This detoxification is believed to improve the overall metabolic function, which can indirectly support weight loss efforts
Based on 4-year data, it appears relatively safe for most people